American Capital And Its Affiliates Invest $10.7 Million In Portfolio Company Halt Medical

Jan 08, 2013, 09:00 ET from American Capital, Ltd.

BETHESDA, Md., Jan. 8, 2013 /PRNewswire/ -- American Capital, Ltd. (Nasdaq: ACAS) ("American Capital") announced today that in December 2012 it invested $6.2 million ($10.7 million including investments by affiliates) in portfolio company Halt Medical, Inc., a medical device company focused on women's health.  The investment supports the commercialization of the Acessa™ System, a newly FDA cleared medical device to treat uterine fibroids.   

"American Capital is pleased to be a part of Halt Medical's continued growth and success in treating uterine fibroids with this additional financing," said Gordon O'Brien, American Capital President, Specialty Finance and Operations.  "The additional capital will support the Company's commercialization of its new revolutionary medical technology for treating millions of women suffering from uterine fibroids, the Acessa™ System.  The Acessa™ System is an alternative to hysterectomy for fibroid patients and is the first FDA cleared product used by gynecologists to treat all fibroid symptoms and types."

American Capital and an affiliate first invested in Halt Medical in May 2007.  Halt Medical is a medical device company focused on establishing a new standard of care for women with symptomatic uterine fibroids.  The Company has developed and launched the Acessa™ System and Procedure, using radiofrequency energy to destroy uterine fibroids.  The results of both U.S. and international trials have led to the clearance of the product by the FDA for use in percutaneous, laparoscopic coagulation and ablation of soft tissue, including treatment of symptomatic uterine fibroids under laparoscopic ultrasound guidance.  In addition, the System has CE marking in the European Union and is licensed for sale in Canada.  The Company was founded in 2004 and is located in Brentwood, CA.

"We are delighted that American Capital has chosen to once again lead financing for this critical new medical device," said Jeff Cohen, Halt Medical Chief Executive Officer.  "Since the start of our relationship, American Capital has been very supportive of our business model and technology.  This additional investment will enable us to continue to build out the commercial side of our business and expand our market presence in the U.S. and internationally." 

American Capital and its affiliated funds have invested approximately $31 billion in over 540 portfolio companies both directly and in support of leading financial partners in change of control transactions.  For more information about American Capital's portfolio, go to

American Capital is a publicly traded private equity firm and global asset manager.  American Capital, both directly and through its asset management business, originates, underwrites and manages investments in middle market private equity, leveraged finance, real estate and structured products.  American Capital manages $18.6 billion of assets, including assets on its balance sheet and fee earning assets under management by affiliated managers, with $118 billion of total assets under management (including levered assets).  From its eight offices in the U.S. and Europe, American Capital and its affiliate, European Capital, will consider investment opportunities from $10 million to $500 million.  For further information, please refer to

This press release contains forward-looking statements. The statements regarding expected results of American Capital are subject to various factors and uncertainties, including the uncertainties associated with the timing of transaction closings, changes in interest rates, availability of transactions, changes in regional, national or international economic conditions, or changes in the conditions of the industries in which American Capital has made investments.

Gordon O'Brien, President, Specialty Finance and Operations 301 951 6122

SOURCE American Capital, Ltd.